Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Tracy Palmer Berns has joined the company as chief compliance officer. In this role, Ms. Berns will be responsible for the company's ongoing compliance program focusing on policy development and training. She will also collaborate with other members of the executive team to provide strategic counsel related to development of business goals and compliance matters related to Akcea's commercial products and investigational therapies.